Bristol-Myers upgraded to Outperform from Market Perform at BMO Capital BMO Capital upgraded Bristol-Myers based on a more positive outlook for its IO pipeline and reduced expectations following the Checkmate-012 trial update. Price target is $50.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.
Teva launches generic Baraclude in U.S. Teva (TEVA) announces the launch of the generic equivalent to Baraclude tablets in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude is marketed by Bristol-Myers Squibb (BMY).